Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) is now available.
EBR Systems, Inc. has received FDA approval for its WiSE System, supported by a Breakthrough Device Designation and compelling clinical data, positioning the company for significant growth. The company is launching a pilot program and plans a Limited Market Release in Q4 2025, supported by strong reimbursement strategies, including CMS-approved NTAP and TPT payments starting in October 2025, and is constructing a new manufacturing facility to support commercial growth, expected to be fully operational by mid-2026.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc. is a developer of the world’s first and only leadless pacemaker designed for heart failure, listed on the ASX since 2021 and registered with the SEC since 2024. The company focuses on a significant market opportunity in the US, targeting an initial addressable market of $3.6 billion with its unique WiSE System, which complements other cardiac pacing devices and is the only leadless device capable of pacing the left ventricle for heart failure.
Average Trading Volume: 707,235
Technical Sentiment Signal: Buy
Find detailed analytics on EBR stock on TipRanks’ Stock Analysis page.